DEP® irinotecan IO/PARP combination data presented at AACR (ASX Announcement)
Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® irinotecan combination data poster, showcasing the recently announced1 data for DEP® irinotecan in combination with leading anticancer therapies, including immuno-oncology (IO) agents, in human colorectal cancer (CRC) models.
DEP® irinotecan clinical data presented at AACR meeting (ASX Announcement)
Starpharma today provides a copy of the DEP® irinotecan clinical poster, highlighting the recently announced1 positive interim clinical data from Starpharma’s Phase 1/2 clinical trial, which demonstrated durable anti-tumour responses in advanced colorectal cancer (CRC) and platinum-resistant/refractory ovarian cancer.
DEP® theranostic presented at international oncology meeting (ASX Announcement)
Starpharma today provides a copy of the poster that showcases the results from a study of DEP® HER2-zirconium, Starpharma’s HER2-targeted radiodiagnostic candidate, which demonstrated a favourable biodistribution profile, with excellent imaging contrast between tumour and normal tissues, as well as rapid uptake and high levels of tumour accumulation in a HER2+ breast cancer model.
DEP® irinotecan combination data to be presented at international oncology conference (ASX Announcement)
Starpharma today announces the presentation of data that demonstrate the benefits of combining DEP® irinotecan with other important classes of anti-cancer therapies, including immuno-oncology (IO) agents, in models of human colorectal cancer.
Change of Company Secretary (ASX Announcement)
Starpharma today announces, in accordance with ASX Listing Rule 3.16.1, that Tracy Weimar has resigned as Company Secretary, a role that was conducted for an interim period.
Appendix 4G – Corporate Governance Statement (ASX Announcement)
Starpharma today releases its Appendix 4G – Key to Disclosures Corporate Governance Council Principles and Recommendations, in accordance with ASX Listing Rules 4.7.3 and 4.10.3.
Starpharma to receive A$6.5M from Mundipharma and rights to VivaGel® BV (ASX Announcement)
Starpharma today announces it has negotiated a commercial settlement agreement with Mundipharma in relation to the VivaGel® BV product.
Starpharma partners with UQ to advance DEP® radio pipeline (ASX Announcement)
Starpharma today announces it has entered a new partnership with The University of Queensland’s (UQ’s) Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR Hub), which has been awarded $4.8 million from the Australian Government’s Australian Research Council (ARC).
DEP® HER2-radiodiagnostic shows imaging benefits (ASX Announcement)
Starpharma today announces that DEP® HER2-zirconium, its HER2-targeted radiodiagnostic candidate, has demonstrated a favourable biodistribution profile, with excellent imaging contrast between tumour and normal tissues, as well as rapid uptake and high levels of tumour accumulation in a HER+ breast cancer model.
Clinical trial update (ASX Announcement)
A voluntary partial clinical hold has been implemented on a trial in which Starpharma (ASX: SPL, OTCQX: SPHRY) technology is used: AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological Malignancies (NCT04865419).